Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma

Journal of Hepatology

Volumn 58, Issue 1, 2013, Pages 169-177

  Jiang, Tao ^a,b   Zhu, Andrew X ^c   Sahani, Dushyant V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB; CETUXIMAB; CONTRAST MEDIUM; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY; SHU 508; SONOVUE; SORAFENIB; SUNITINIB; YTTRIUM 90;

ARTIFICIAL EMBOLISM; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CELL DIFFERENTIATION; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; DRUG EFFICACY; DYNAMIC CONTRAST ENHANCED ULTRASONOGRAPHY; DYNAMIC CONTRAST ENHANCEMENT; ECHOGRAPHY; HUMAN; IN VIVO STUDY; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; REVIEW; SYMPTOM; TISSUE PERFUSION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DRUG MONITORING; HUMANS; LIVER NEOPLASMS; PERFUSION IMAGING;

EID: 84871210163     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.08.022     Document Type: Review

References (73)

1. M.B. Thomas, and A.X. Zhu Hepatocellular carcinoma: the need for progress J Clin Oncol 23 2005 2892 2899
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. A.E. Alsina Liver transplantation for hepatocellular carcinoma Cancer Control 17 2010 83 86
4. R. Lencioni Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies Oncology 78 2010 107 112
5. R.S. Finn Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 16 2010 390 397
6. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
7. M.A. Rosen Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities Cancer Biol Ther 9 2010 20 22
8. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
9. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
10. D.M. Koh, and D.J. Collins Diffusion-weighted MRI in the body: applications and challenges in oncology AJR Am J Roentgenol 188 2007 1622 1635
11. A.F. Shields Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology Mol Imaging Biol 8 2006 141 150
12. K. Memon, L. Kulik, R.J. Lewandowski, E. Wang, A. Riaz, and R.K. Ryu Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times Gastroenterology 141 2011 526 535 535, e521-522
13. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
14. S. Faivre, E. Raymond, E. Boucher, J. Douillard, H.Y. Lim, and J.S. Kim Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
15. A.X. Zhu, N.S. Holalkere, A. Muzikansky, K. Horgan, and D.V. Sahani Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma Oncologist 13 2008 120 125
16. A.X. Zhu, K. Stuart, L.S. Blaszkowsky, A. Muzikansky, D.P. Reitberg, and J.W. Clark Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 2007 581 589
17. A.X. Zhu, D.V. Sahani, D.G. Duda, E. di Tomaso, M. Ancukiewicz, and O.A. Catalano Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
18. M.B. Thomas, R. Chadha, K. Glover, X. Wang, J. Morris, and T. Brown Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067
19. H.K. Sanoff, S. Bernard, R.M. Goldberg, M.A. Morse, R. Garcia, and L. Woods Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma Gastrointest Cancer Res 4 2011 78 83
20. C.H. Hsu, T.S. Yang, C. Hsu, H.C. Toh, R.J. Epstein, and L.T. Hsiao Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Br J Cancer 102 2010 981 986
21. P. Hilgard, M. Hamami, A.E. Fouly, A. Scherag, S. Muller, and J. Ertle Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 2010 1741 1749
22. A. Asnacios, L. Fartoux, O. Romano, C. Tesmoingt, S.S. Louafi, and T. Mansoubakht Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study Cancer 112 2008 2733 2739
23. J. Llovet, S. Ricci, and V. Mazzaferro SHARP Investigators. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
24. C. Muller, M. Schoniger-Hekele, R. Schernthaner, B. Renner, M. Peck-Radosavljevic, and A. Brichta Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial Wien Klin Wochenschr 120 2008 608 618
25. M. Molinari, J.R. Kachura, E. Dixon, D.K. Rajan, E.B. Hayeems, and M.R. Asch Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre Clin Oncol (R Coll Radiol) 18 2006 684 692
26. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
27. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
28. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
29. W.L. Monsky, I. Kim, S. Loh, C.S. Li, T.A. Greasby, and L.S. Deutsch Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization AJR Am J Roentgenol 195 2010 1220 1230
30. S.A. Sohaib, B. Turner, J.A. Hanson, M. Farquharson, R.T. Oliver, and R.H. Reznek CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size Br J Radiol 73 2000 1178 1184
31. A. Forner, C. Ayuso, M. Varela, J. Rimola, A.J. Hessheimer, and C.R. de Lope Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
32. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
33. A. Riaz, K. Memon, F.H. Miller, P. Nikolaidis, L.M. Kulik, and R.J. Lewandowski Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation J Hepatol 54 2011 695 704
34. R. Gillmore, S. Stuart, A. Kirkwood, A. Hameeduddin, N. Woodward, and A.K. Burroughs EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
35. J.W. Park, R.S. Finn, J.S. Kim, M. Karwal, R.K. Li, and F. Ismail Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 17 2011 1973 1983
36. J. Edeline, E. Boucher, Y. Rolland, E. Vauleon, M. Pracht, and C. Perrin Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma Cancer 118 2012 147 156
37. T. Jiang, A. Kambadakone, N.M. Kulkarni, A.X. Zhu, and D.V. Sahani Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST) Invest Radiol 47 2012 11 17
38. S. Quiroga, C. Sebastia, E. Pallisa, E. Castella, M. Perez-Lafuente, and A. Alvarez-Castells Improved diagnosis of hepatic perfusion disorders: value of hepatic arterial phase imaging during helical CT Radiographics 21 2001 65 81 questionnaire 288-294
39. K.W. Sniderman Hepatocellular carcinoma with portal vein tumor thrombus Radiology 207 1998 552 553
40. R. Kloeckner, G. Otto, S. Biesterfeld, K. Oberholzer, C. Dueber, and M.B. Pitton MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2010 532 540
41. H. Choi, C. Charnsangavej, S.C. Faria, H.A. Macapinlac, M.A. Burgess, and S.R. Patel Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759
42. H. Choi, C. Charnsangavej, S. De Castro Faria, E.P. Tamm, R.S. Benjamin, and M.M. Johnson CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol 183 2004 1619 1628
43. R.S. Benjamin, H. Choi, H.A. Macapinlac, M.A. Burgess, S.R. Patel, and L.L. Chen We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764
44. S. Faivre, M. Zappa, V. Vilgrain, E. Boucher, J.Y. Douillard, and H.Y. Lim Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib Clin Cancer Res 17 2011 4504 4512
45. M. Kudo Imaging blood flow characteristics of hepatocellular carcinoma Oncology 62 2002 48 56
46. K.A. Miles, M.P. Hayball, and A.K. Dixon Functional images of hepatic perfusion obtained with dynamic CT Radiology 188 1993 405 411
47. A.R. Kambadakone, and D.V. Sahani Body perfusion CT: technique, clinical applications, and advances Radiol Clin North Am 47 2009 161 178
48. B. Morgan, A.L. Thomas, J. Drevs, J. Hennig, M. Buchert, and A. Jivan Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 2003 3955 3964
49. H.W. van Laarhoven, M. Rijpkema, C.J. Punt, T.J. Ruers, J.C. Hendriks, and J.O. Barentsz Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases J Magn Reson Imaging 18 2003 315 320
50. G. Chen, D.Q. Ma, W. He, B.F. Zhang, and L.Q. Zhao Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma World J Gastroenterol 14 2008 5738 5743
51. D.V. Sahani, N.S. Holalkere, P.R. Mueller, and A.X. Zhu Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - initial experience Radiology 243 2007 736 743
52. H.J. Jiang, H.B. Lu, Z.R. Zhang, Y.M. Wang, Q. Huang, and Y.H. Huang Experimental study on angiogenesis in a rabbit VX2 early liver tumour by perfusion computed tomography J Int Med Res 38 2010 929 939
53. C.Y. Hsu, Y.C. Shen, C.W. Yu, C. Hsu, F.C. Hu, and C.H. Hsu Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil J Hepatol 55 2011 858 865
54. D. Choi, H.K. Lim, W.J. Lee, S.H. Kim, Y.H. Kim, and J.H. Lim Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultrasonography with a microbubble contrast agent J Ultrasound Med 22 2003 1163 1172
55. G. Salvaggio, A. Campisi, V. Lo Greco, I. Cannella, M.F. Meloni, and G. Caruso Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT Abdom Imaging 35 2010 447 453
56. N. Lassau, S. Koscielny, L. Chami, M. Chebil, B. Benatsou, and A. Roche Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification - preliminary results Radiology 258 2011 291 300
57. K.W. Ferrara, C.R. Merritt, P.N. Burns, F.S. Foster, R.F. Mattrey, and S.A. Wickline Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents Acad Radiol 7 2000 824 839
58. T. Kodama, N. Tomita, Y. Yagishita, S. Horie, K. Funamoto, and T. Hayase Volumetric and angiogenic evaluation of antitumor effects with acoustic liposome and high-frequency ultrasound Cancer Res 71 2011 6957 6964
59. S. Goshima, M. Kanematsu, H. Kondo, R. Yokoyama, Y. Tsuge, and Y. Shiratori Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 27 2008 834 839
60. I.R. Kamel, D.A. Bluemke, J. Eng, E. Liapi, W. Messersmith, and D.K. Reyes The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma J Vasc Interv Radiol 17 2006 505 512
61. T.K. Rhee, N.K. Naik, J. Deng, B. Atassi, M.F. Mulcahy, and L.M. Kulik Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging J Vasc Interv Radiol 19 2008 1180 1186
62. C. Schraml, N.F. Schwenzer, P. Martirosian, M. Bitzer, U. Lauer, and C.D. Claussen Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results AJR Am J Roentgenol 193 2009 W301 W307
63. Z. Yuan, X.D. Ye, S. Dong, L.C. Xu, X.Y. Xu, and S.Y. Liu Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma Eur J Radiol 75 2010 e9 e14
64. K. Kubota, T. Yamanishi, S. Itoh, Y. Murata, K. Miyatake, and H. Yasunami Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma Oncol Rep 24 2010 727 732
65. A.R. Padhani, G. Liu, D.M. Koh, T.L. Chenevert, H.C. Thoeny, and T. Takahara Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 2009 102 125
66. J.N. Talbot, L. Fartoux, S. Balogova, V. Nataf, K. Kerrou, and F. Gutman Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease J Nucl Med 51 2010 1699 1706
67. Y. Kuang, N. Salem, H. Tian, J.A. Kolthammer, D.J. Corn, and C. Wu Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11c]choline: correlation with in vivo metabolic studies J Nucl Med 52 2011 98 106
68. Y. Yamamoto, Y. Nishiyama, R. Kameyama, K. Okano, H. Kashiwagi, and A. Deguchi Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET J Nucl Med 49 2008 1245 1248
69. T. Torizuka, N. Tamaki, T. Inokuma, Y. Magata, Y. Yonekura, and A. Tanaka Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy J Nucl Med 35 1994 1965 1969
70. B. Paudyal, N. Oriuchi, P. Paudyal, Y. Tsushima, Y. Iida, and T. Higuchi Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy Oncol Rep 18 2007 1469 1473
71. T. Higashi, E. Hatano, I. Ikai, R. Nishii, Y. Nakamoto, and K. Ishizu FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma Eur J Nucl Med Mol Imaging 37 2010 468 482
72. H. Young, R. Baum, U. Cremerius, K. Herholz, O. Hoekstra, and A.A. Lammertsma Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1773 1782
73. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 2009 122S 150S